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Available online 15 June 2016Objectives: To determine security and benefits of high pressure postdilatation (HPP) of bioresorbable vascular
scaffolds (BVS) in percutaneous coronary intervention (PCI) of complex lesions whatever its indication is.
Background: Acute scaffold disruption has been proposed as the main limitation of BVS when they are
overexpanded. However, clinical implications of this disarray are not yet clear and more evidence is needed.
Methods: A total of 25 BVS were deployed during PCI of 14 complex lesions after mandatory predilatation. In all
casesHPPwas performedwithNC balloon in a 1:1 relation to the artery. After that, optical coherence tomography
(OCT) analyses were performed.
Results: Mean and maximal postdilatation pressure were 17 ± 3.80 and 20 atmospheres (atm) respectively.
Postdilatation balloon/scaffold diameter ratio was 1.01.
A total of 39,590 struts were analyzed. Mean, minimal andmaximal scaffold diameter were respectively: 3.09±
0.34 mm, 2.88 ± 0.31 mm and 3.31 ± 0.40 mm. Mean eccentricity index was 0.13 ± 0.05. ISA percentage was
1.42%with a total of 564malapposed struts. 89 strutswere identifiedas disrupted,which represents a percentage
of disrupted struts of 0.22%.
At 30 days, none of our patients died, suffered from stroke, stent thrombosis or needed target lesion revascular-
ization (TLR).
Conclusions: NC balloon HPP of BVS at more than 17 atm (up to 20 atm) is safe during PCI and allows to achieve
better angiographic and clinical results.





Newbioresorbable scaffold technology has become the great revolu-
tion in interventional cardiology. These scaffolds consist on a polymericonary angioplasty; DES, drug-
old; OCT, optical coherence to-
target lesion revascularization;
pliant balloon; ISA, incomplete
gy Unit, Universitary Clinical
15706 Santiago de Compostela,
equeiros).
eliability and freedom from bias
.
backbone of poly-L-lactic acid which is coated by another polymeric
layer in which is embedded the antiproliferative drug. They offer all
the benefits of a DES in addition to a great advantage: by two years
after their implantation, the scaffolds are not more present in the coro-
nary artery [1]. Furthermore, the artery can recover its vasomotility and
compliance. Nevertheless, one limitation has been proposed for these
devices: they are at risk of disruption when they are overexpanded.
Clinical implications of this disarray are not yet clear.
2. Methods
2.1. Patient population
In this all-comers prospective study we included fourteen patients
admitted to our centre for percutaneous coronary intervention (PCI)
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with 25 bioresorbable vascular scaffolds (BVS) deployed.
Each patient must has been treated with a minimum of one BVS,
independently of what the indication for coronary revascularization
was. In fact, PCI is accepted either in the setting of an acute coronary
syndrome (with or without ST segment elevation) or in stable coronary
artery disease.
We report baseline clinical and angiographic characteristics of the 14
patients (14 lesions treated) in addition to OCT baseline analyses of the
25 BVS deployed. Moreover, all patients have undergone a 30-day
clinical follow up, and half of them have also been interviewed three
months after intervention.
Regarding to anatomical lesions characteristics, we only excluded
lesions when minimum vessel diameter was less than 2 mm or when
maximum vessel diameter exceeded 4 mm. Other exclusion criteria
include: heparin or aspirin intolerance, high risk of bleeding (patients
under chronic anticoagulation treatment, with previous history of life-
threatening bleeding or with coagulation diseases), patients expected
not to be able to maintain long dual antiplatelet treatment( DAPT) and
terminal disease with life-expectancy less than a year.
2.2. Devices and optical coherence tomography
In our study we only used the Abbot bioresorbable scaffold (Abbott
Vascular, Santa Clara, California): the Absorb 1.1 BVS. This device con-
sists on a polymeric backbone of poly-L-lactic acid which is coated by
another polymeric layer. This external layer is the one which supports
and controls the everolimus eluting process. The scaffold is available
in different diameters (2.5, 3.0, 3.5 mm) and lengths (15, 18, 23 and
28 mm), and we have chosen the most appropriate ones according to
each lesion characteristics. Radial tension of this bioresorbable device
is comparable to previously described radial tension in most bare
metal stents. Its strut thickness has been quantified in 156 μm and its
mean contact area with the vessel is 25% [1].
Intravascular imaging evaluation has been performed by a
frequency-domain OCT analysis. We used the Lunawave Coronary
imaging console® (Terumo Corp., Tokyo, Japan) and the FastView
Catheter®( Terumo Corp. Tokyo, Japan). This catheter is advanced
distally to the scaffold area at least 5 mm and then, it is automatically
pulled back with simultaneous infusion of 4–10 mL of iodinated
contrast at a rate of 3-5 ml/s. In very large stented artery segments,
consecutive pullbacks can be performed in order to allow an adequate
assessment of the treated segment. We performed the pullback at a
20 mm/s speed. In each pullback the achieved frame rate was 160
frames /sec.
2.3. Procedure
Scaffold size was selected according to visual and QCA assessment
and, if more than one scaffold were needed, they must be implanted
overlapping. According to current recommendations, all lesions must
be predilatated with semicompliant balloons before scaffold deploy-
ment. In addition to this, all devices were postdilatated at high pressure
with a non-compliant (NC) balloon in a 1:1 relationship. In our cathlab
two brands of non-compliant balloons are available: Open NC® super
High Pressure PTCA balloon Sismedical AG Winterthur Switzerland
and NC Trek® Coronary Dilatation Catheter Abbott Vascular Sta. Clara
California. A minimum pressure of, at least, 10 and 12 atm were used
to achieve minimum diameter of each balloon. Maximal expected
diameter for 3 mm and 3.5 mm Open NC balloon were 3.36 mm and
3.78, maximal expected diameter for 3 and 3.5 mm NC Trek balloon
were 3.21 and 3.78 mm respectively. Election of posdilatation balloon
was defined by its availability at the moment of the PCI. After that,
OCT analyses were performed as it was explained above.
In our study we enrolled patients with indication of PCI either in the
setting of an acute coronary syndrome or for chronic coronary arterydisease. Primary PCIwas performedby an on-call group of intervention-
al cardiologists, according to current guidelines. Thrombus aspiration
was not mandatory in all culprit lesions and GP IIbIIIA inhibitors could
be used in a bail-out indication.
All percutaneous coronary interventions have been performed
under unfractioned heparin treatment. At discharge, dual antiplatelet
therapy was mandatory with aspirin and a P2Y12 inhibitor (ticagrelor,
prasugrel or clopidogrel). Of note, in line with current guidelines, new
generation P2Y12 inhibitors should be used after PCI in acute coronary
syndrome.
2.4. OCT offline analysis
The OCT analysis was performedwith the off-line software provided
by Terumo® (Terumo Corp., Tokyo, Japan). Wemeasured 1mm distally
and proximally out of the stented vessel segment, and the total
scaffolded segment. Each millimeter of the pullback contains 8 frames.
In the 1 mm proximal and distal to the BVS edge we measured for
each frame: lumen and vessel area and diameter. These data allowed
us to calculate mean lumen and vessel area and mean, maximum and
minimum lumen and vessel diameters.
For each frame along the scaffolded segment of the vessel, we mea-
sured all parameters mentioned above, in addition to scaffold area and
diameter.
Automatically, Terumo software provided us plaque area, maximum
and minimum plaque thickness and eccentricity index. OCT baseline
analysis has been done according to previous literature [2–5] in offline
setting. We defined lumen area as delimitated by the endoluminal
surface of the struts. In case of malapposed struts were present, at that
angular section of the vessel, lumen area would be delimitated by the
endoluminal wall of the vessel. Scaffold area was measured thanks to
the circumference formed by the points in the middle of the black
core of each strut. Vessel area has been described based on the circum-
ferencemarked by external elasticmembrane. In those caseswhere this
membrane was not so clear in first pullback, we performed additional
pullbacks until its correct visualization. Incomplete strut apposition
(ISA) was considered when axial distance between the abluminal
surface of struts and the endoluminal surface of the vessel wall was
larger than strut thickness (in our case: 156 μm) [6].
Acute scaffold disruption was diagnosed when two struts were in
the same angular sector of the lumen either if they were in contact
(“stacked struts”, Fig. 1) or if they were one above the other but with
a space between them (“overhung struts”). In addition to this, isolated
malapposed struts (Fig. 2) were also considered as a mark of scaffold
disruption when they were alone in lumen, with no connection with
the stent circumference [7,8].
Thanks to all previous data we calculate all the following parame-
ters: percentage of ISA (defined as the percentage of malapposed struts
from the total of struts) [6] and percentage of disrupted struts from the
total number of struts.
2.5. Study endpoints
Primary endpoint: to determine the percentage of disrupted struts
after postdilatation of a BVS in percutaneous coronary intervention
(PCI).
Secondary endpoints: to determine the percentage of malapposed
struts after postdilatation, and rates of mortality, stroke or target lesion
revascularization (TLR) at 30 days.
2.6. Statistical analyses
In this report we include results from both strut-level and lesion-
level analyses. Continuous variables were expressed as mean and
standard deviation while categorical variables are presented as a
Fig. 1. Image of stacked disrupted strut. Letter A marks “stacked strut” type disruption from one of the analyzed BVS.
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version 21.
3. Results
Fourteen patients were included in this first report of our study. 25
BVS were deployed in 14 treated lesions. All baseline clinical character-
istics are included in Table 1. Most patients were men (only 2 from 14
were women), with a mean age of 56 years old and almost 43% ofFig. 2. Image of an isolated disrupted strut. Example of athem have been smokers in the past. Attending to cardiovascular main
risk factors: 57.1% had arterial hypertension, 78.6% suffered from
dyslipidemia and 28.6% were diabetic (all of them in treatment with
oral antidiabetic drugs). It is remarkable that all of them have a body
mass index equal or higher than 25, which means all of them were
overweight.
Themost frequent indication for PCI was effort angina (50%), never-
theless we want to notice that almost a third of the total population
(28.6%) were patients who presented at our center with STEMI, socute strut disruption presented as an isolated strut.
Table 1
Clinical characteristics of our patients.
Number of patients n:14
Age (years) 56.79 ± 11.38
Women n( %) 2 (14.3)






Arterial hypertension n( %) 8 (57.1)
Dislypemia n (%) 11 (78.6)
Diabetes Mellitus on AOD n(%)










Previous stroke n(%) 0
Peripheral artery disease n (%) 1 (7.1)
Atrial fibrillation n(%) 0
Previous CAD n (%)
Previous target vessel revascularization
1(7.1)
0
HbA1c % 6.05 ± 0.99
Haemoglobine g/dL 14,72 ± 0.82
Platelets × 103/μL 270,071 ± 93,403





Previous treatment with statins n (%) 3 (21.4)
Mortality rate at 30 days % 0
Stroke rate at 30 days % 0
This table includes all baseline clinical characteristics of the patients included.




Current indication for PCI n (%)
Effort angina










Mean vessel diameter mm 3.46 ± 0.23
Thrombus n (%) 4 (28.6)
Predilatation n (%) 14 (100)
Mean diameter balloon predilatation mm 3.2 ± 0.36
Mean length balloon predilatation mm 19.2 ± 4.37
Mean predilation balloon pressure atm 12.4 ± 3.04
Mean number of BVS deployed per lesion 1.79
Mean diameter of BVS mm 3.22 ± 0.32
Mean length of BVS mm 22.5 ± 5.34
Mean total length scaffolded per lesion mm 40.21 ± 22.14
Mean pressure used in BVS deployment atm 14.08 ± 2.73
Postdilatation n (%) 14 (100)
Mean diameter of postdilatation balloons mm 3.5 ± 0.32
Mean length of postdilatation balloons mm 13 ± 3.55
Mean postdilatation balloon pressure atm 17 ± 3.80
Maximum postdilatation balloon pressure atm
Postdilatation balloon/scaffold diameter ratio
20 ± 3.80
1.01









Post-PCI TIMI III flow n(%) 14 (100)







Bifurcations n(%) 3 (21.4)
Chronic total occlusions n(%) 3 (21.4)
Target lesion revascularization at 30 days % 0
This table includes the most important procedural aspects of the performed PCI.
ACS: acute coronary syndrome BVS: bioresorbable vascular scaffold, PCI: percutaneous
coronary intervention STEMI: ST segment elevation myocardial infarction.
Table 3
Baseline OCT measurements within stented segment of the vessel.
Total number of BVS: 25
Mean lumen area mm2 6.84 ± 1.64
Mean lumen diameter mm 2.93 ± 0.35
Minimal lumen diameter mm 2.71 ± 0.72
Maximal lumen diameter mm 3.15 ± 0.41
Mean vessel area mm2 13.1 ± 2.88
Mean vessel diameter mm 4.04 ± 0.46
Minimal vessel diameter mm 3.88 ± 0.44
Maximal vessel diameter mm 4.21 ± 0.49
Mean scaffold area mm2 7.59 ± 1.64
Mean scaffold diameter mm 3.09 ± 0.34
Minimal scaffold diameter mm 2.88 ± 0.31
Maximal scaffold diameter mm 3.31 ± 0.40
Mean plaque area mm2 6.17 ± 1.79
Maximal plaque thickness mm 0.80 ± 0.16
Minimal plaque thickness mm 0.36 ± 0.10
Mean eccentricity index 0.13 ± 0.05
Total number of struts 39,590
Disrupted struts 89
Malapposed struts 564
Percentage of disrupted struts % 0.22
Percentage of ISA % 1.42
This table includes the results of baseline intracoronary studies by OCT within
the stented segments.
BVS: bioresorbable vascular scaffold ISA: incomplete strut apposition.
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previously diagnosed of coronary artery disease, with no target vessel
revascularization before.
Baseline angiographic data are showed in Table 2. None of our
patients has undergone circumflex artery revascularization, being the
most frequent treated artery: the anterior descendent one (9 of 14
patients), with a mean artery size of 3.46 mm. Only patients with
STEMI had initial TIMI flow 0 with angiographic thrombus. 100% of
our patients received predilatation of the coronary lesion. In most
cases one or two devices were deployed, with only one case where 4
stents were needed. Mean treated vessel distance was 40.21 mm. In
100% of cases, postdilatation was performed with one of the two
available balloons previously described, with a mean length of 13 mm.
Mean postdilatation balloon pressure was 17 atmospheres (atm), with
a maximal postdilatation pressure of 20 atm. Postdilatation balloon/
scaffold diameter ratio was 1.01. Exceptional angiographic results
were achieved with a TIMI III flow in all cases.
All OCT baseline measurements are collected in Table 3. A total of
39,590 struts were analyzed within a total of 563 mm of stented vessel
in 25 BVS. We detected acute disruption of the scaffold in three of
fourteen treated lesions, with a total number of disrupted struts of 89.
The percentage of disrupted struts was 0.22%. Malapposition of the
scaffold was detected in 3 treated lesions. The total number of
malapposed struts was 564. ISA percentage was estimated of 1.42%.
Mean, minimal and maximal scaffold diameter were respectively:
3.09± 0.34mm, 2.88± 0.31mmand 3.31± 0.40mm.Mean eccentric-
ity index was 0.13 ± 0.05.
4. Discussion
Interventional cardiology has experienced great development since
Grüentzig introduced PTCA in 1977 [9]. The main problem of this
technique is the high likelihood of acute reocclusion due to elastic recoil
of the vessel. In order to avoid these complications, first bare metal
stentswere introduced in late eighties. Either acute recoil or constrictive
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tension [10]. However, therewas a negative point on them: an excessive
healing arterial processwhich results in a reduction in lumen area.With
the development of DES, intimal hyperplasia is controlled [11], with the
only problem of a higher risk of arterial thrombosis , which is mitigate
with longer dual antiplatelet therapies.
Since theywere introduced at the beginning of this decade, BVShave
become some of the most promising devices in interventional cardiolo-
gy. They offer all the previous stents ‘ beneficial properties in addition to
one significant difference: the resorption of their polymeric strut at
2 years after its implantation [1].
The disappearance of the strut lets the vessel to restore its own
vasomotility and compliance and it is followed by an increased luminal
area. Moreover, the no longer existence of the scaffold would allow
future coronary revascularization surgery if necessary [12].
However, the main drawback of the BVS is its low radial tension
strength. First generation everolimus bioresorbable vascular scaffolds
(Absorb 1.0 Abbott Vascular, Santa Clara, California) only offered
adequate radial support for the first post-implantation weeks [1]. Its
mean percent acute recoil was 6.85 ± 6.96%, which represented a
significant higher rate of acute recoil versus metallic everolimus-
eluting stents ( e.g. XienceV stent®, Abbott Vascular, Santa Clara, Califor-
nia) which has a mean percent acute recoil of 4.27 ± 7.08%) [13]. In ad-
dition to this, intracoronary imaging studies demonstrated that first
generation Absorb 1.0 devices had a high late luminal loss (LLL) of
0.44mmat sixmonths (versus 0.10mmof six-months LLL for the Xience
V stent). In order to correct these defaults, second generation Absorb 1.1
was redesigned. New distribution of the scaffold struts allows to reduce
themaximumcircular unsupported cross sectional area and some chem-
ical variations of the polymer (which imply a slower polymeric hydroly-
sis process) let the scaffold maintain its radial tension for a longer period
of time [1]. Nevertheless, BVS radial strength remains slightly lower than
metallic ones do, and this is the reason why optimal predilatation of the
lesion before the scaffold deployment should be done. 100% of lesions
treated in our study were predilatated without complications, being
the mean balloon pressure applied of 12.4 atm.
However, there is no general consensus between interventional car-
diology community about the necessity of high pressure postdilatation
after the BVS deployment. Previous evidence had recognized risk ofFig. 3.Resolution of scaffoldmalapposition after postdilatation. Imagen 3Ademonstrates thepre
3B ISA was corrected and right expansion of the BVS was achieved.strut rupture as the main limitation of these kind of devices. For the
first time, Absorb A trial investigators reported a single case of strut
disruption in a patient with persistent angina. They proposed this
complication was related to over –expansion of the device [14]. Going
along with this theory, in 2011 Ormiston et al. [15] reported a case of
strut disruption in a second generation BVS: an Absorb 1.1 scaffold
which had been postdilatated for two times at 24 atm and 16 atm.
Further studies with second generation BVS also show low rates of
strut disruption but only in OCT analyses, not on IVUS ones [2,3].
Although clinical implications of these changes were not clear, BVS
were not recommended to be overexpanded by high pressure balloon
post-dilatation process in order to avoid acute struts disruption.
However, clinical evidence has reported same angiographical and OCT
findings as risk factors for intrastent thrombosis either in DES or BVS:
stent underexpansion, malapposition and incomplete strut coverage
[16]. In this line, Campodanno et al. [17].have recently reported high
rates of intrastent thrombosis for BVS (1.5% at 30 days, 2.1% at six
months) however we consider necessary to point out that only 49% of
treated lesions had been postdilatated.
We support the importance of postdilatation when BVS is deployed
in order to avoid incomplete apposition of the device and further
complications related to this like aforementioned ones (Fig. 3). We
postdilatated at high pressure the 100% of the 25 BVS deployed. Thanks
to a mean high postdilatation pressure of 17 atm. we achieved a very
low rate of malapposition of the scaffolds implanted. ISA percentage
showed by OCT analyses was 1.42% ( in line with recent published
studies [8]).
Acute scaffold disruptionwas also evaluated by OCT images. Although
high postdilatation pressure was applied to the 25 BVS, only 89 struts
from a total of 39,590 were identified as disrupted, what represents a
minimal percentage of disrupted struts of 0.22%. Previous studies had al-
ready reported low rates of acute scaffold disruption after BVS deploy-
ment [7]. Nevertheless, low rates of postdilatation were suggested as
the main reason of this low frequency complication (e.g. only 57% of
total lesions underwent postdilatation in Yosinobu et al. study [7]).
Based on our results (which are consistent with one recently
published study reported by Fabris et al. [8].) we can state acute struts
disruption is a very uncommon technical complication after high
pressure postdilatation of BVS.sence ofmalapposed struts after BVS deployment. After high pressure postdilatation, in Fig.
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performed very high pressure postdilatation of the BVS (up to a
maximal balloon inflation of 28 ± 3.8 atm) without procedural
complications, our OCT results are better. With a lower mean
postdilatation pressure of 17 atm (being the maximal pressure applied
20 atm) in our study, we achieved larger luminal and scaffold areas
(6.84 ± 1.64 mm2 Vs 6.79 ± 1.4 mm2 and 7.59 ± 1.64 mm2 Vs
6.83 ± 1.42 mm2 respectively) and slightly larger values for mean,
minimal and maximal scaffold diameters (3.09 ± 0.34, 2.88 ± 0.31,
3.31± 0.40mmVs 2.9±0.31, 2.7± 0.28 and 3.1± 0.36). Furthermore,
we achieved better results attending to eccentricity index (0.13 ± 0.05
Vs 0.86 ± 0.02) with a lower percentage of ISA (1.42% vs1.84%).
From our knowledge, the present study is the first one which
correlates angiographic and OCT data with clinical follow up of the
patient. In addition to this, we find it of special clinical relevance as
it is the first one which includes a real-world cohort of patients
with no exclusion criteria related to indication of coronary revascu-
larization or type of coronary lesion. Patients who underwent prima-
ry PCI had been excluded previously from studies on scaffold
disruption [7,8]; however, 28.6% of our study population are STEMI
patients (Fig. 4). We neither did exclude bifurcations (21.4%),
chronic total occlusions (21.4%) or aorto-ostial lesions. In fact,
Szabo technique was performed in treatment of two different
proximal LAD lesions, with excellent angiographic result, as recently
described by our group.
Besides, our study is the one which includes the highest percentage
of complex lesions: 85,7% of the total treated lesions are type C
according to ACC/AHA criteria( with no A type lesions treated) with a
mean length of stented vessel by lesion of 40.21 mm.
Nevertheless, even in presence of such complexity, none of our pa-
tients died, suffered from stroke, stent thrombosis or needed TLR inFig. 4. Embedded BVS after primary PCI. The image shows an adequate expansion of BV30 days after intervention. Neither did those who complete a
3 months-follow-up.
At sight of the reported data, we can state postdilatation at high
pressure with NC balloon is safe in PCI with BVS and It lets us achieve
better angiographical and clinical results even in complex lesions.
Although more evidence is needed, we propose high pressure
postdilatation of BVS in order to avoid malapposition and to acquire
correct expansion of the device, especially in those lesions with high
probability of reocclusion like CTO or very long lesions (e.g. more
than 20 mm).
5. Limitations
While we acknowledge that the study major limitation is the rela-
tively small number of patients included, we want to highlight we
reviewed 25 BVS with a very high total number of struts analyzed
(39,590). We expect to support the results achieved with the inclusion
of new patients in the near future. Another limitation of the study
comes from the fact that it is a single-center study.
6. Conclusion
High pressure postdilatation between 17 to 20 atm. with NC balloon
of BVS, is safe and improves angiographical and clinical results in PCI of
complex coronary lesions.
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